Cargando…

Dehydroabietic Acid Microencapsulation Potential as Biofilm-Mediated Infections Treatment

The antimicrobial activity of dehydroabietic acid (DHA) for its use as an antibiofilm agent was tested in this work. DHA was assayed against a collection of Gram-positive, Gram-negative sensitive and resistant bacteria and yeasts through the minimum inhibitory concentration (MIC), MIC with Bioburden...

Descripción completa

Detalles Bibliográficos
Autores principales: Neto, Iris, Domínguez-Martín, Eva María, Ntungwe, Epole, Reis, Catarina P., Pesic, Milica, Faustino, Célia, Rijo, Patrícia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229915/
https://www.ncbi.nlm.nih.gov/pubmed/34199531
http://dx.doi.org/10.3390/pharmaceutics13060825
_version_ 1783713083518091264
author Neto, Iris
Domínguez-Martín, Eva María
Ntungwe, Epole
Reis, Catarina P.
Pesic, Milica
Faustino, Célia
Rijo, Patrícia
author_facet Neto, Iris
Domínguez-Martín, Eva María
Ntungwe, Epole
Reis, Catarina P.
Pesic, Milica
Faustino, Célia
Rijo, Patrícia
author_sort Neto, Iris
collection PubMed
description The antimicrobial activity of dehydroabietic acid (DHA) for its use as an antibiofilm agent was tested in this work. DHA was assayed against a collection of Gram-positive, Gram-negative sensitive and resistant bacteria and yeasts through the minimum inhibitory concentration (MIC), MIC with Bioburden challenge, minimum bactericidal concentration (MBC), minimum biofilm inhibitory concentration (MBIC), MBIC with Bioburden challenge and growth curve studies. Toxicological studies (Artemia salina, sulforhodamine B (SRB) assay) were done to assess if the compound had antimicrobial and not cytotoxic properties. Furthermore, microencapsulation and stability studies were carried out to evaluate the chemical behavior and stability of DHA. On MIC results, Gram-positive bacteria Staphylococcus aureus ATCC 1228 and Mycobacterium smegmatis ATCC 607 presented a high efficiency (7.81 µg/mL), while on Gram-negative bacteria the highest MIC value of 125 µg/mL was obtained by all Klebsiella pneumoniae strains and Escherichia coli isolate strain HSM 303. Bioburden challenge showed that MIC, MBIC and percentage biofilm inhibition (BI) values suffered alterations, therefore, having higher concentrations. MBIC values demonstrated that DHA has a higher efficiency against S. aureus ATCC 43866 with a percentage of BI of 75.13 ± 0.82% at 0.49 µg/mL. Growth curve kinetic profiles of DHA against S. aureus ATCC 25923 were observed to be bacteriostatic. DHA-alginate beads had a average size of 2.37 ± 0.20 and 2.31 ± 0.17 × 10(3) µm(2) with an encapsulation efficiency (EE%) around 99.49 ± 0.05%, a protection percentage (PP%) of 60.00 ± 0.05% in the gastric environment and a protection efficiency (PE%) around 88.12 ± 0.05% against UV light. In toxicological studies DHA has shown IC(50) of 19.59 ± 7.40 µg/mL and a LC(50) of 21.71 ± 2.18%. The obtained results indicate that DHA is a promising antimicrobial candidate against a wide range of bacteria and biofilm formation that must be further explored.
format Online
Article
Text
id pubmed-8229915
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82299152021-06-26 Dehydroabietic Acid Microencapsulation Potential as Biofilm-Mediated Infections Treatment Neto, Iris Domínguez-Martín, Eva María Ntungwe, Epole Reis, Catarina P. Pesic, Milica Faustino, Célia Rijo, Patrícia Pharmaceutics Article The antimicrobial activity of dehydroabietic acid (DHA) for its use as an antibiofilm agent was tested in this work. DHA was assayed against a collection of Gram-positive, Gram-negative sensitive and resistant bacteria and yeasts through the minimum inhibitory concentration (MIC), MIC with Bioburden challenge, minimum bactericidal concentration (MBC), minimum biofilm inhibitory concentration (MBIC), MBIC with Bioburden challenge and growth curve studies. Toxicological studies (Artemia salina, sulforhodamine B (SRB) assay) were done to assess if the compound had antimicrobial and not cytotoxic properties. Furthermore, microencapsulation and stability studies were carried out to evaluate the chemical behavior and stability of DHA. On MIC results, Gram-positive bacteria Staphylococcus aureus ATCC 1228 and Mycobacterium smegmatis ATCC 607 presented a high efficiency (7.81 µg/mL), while on Gram-negative bacteria the highest MIC value of 125 µg/mL was obtained by all Klebsiella pneumoniae strains and Escherichia coli isolate strain HSM 303. Bioburden challenge showed that MIC, MBIC and percentage biofilm inhibition (BI) values suffered alterations, therefore, having higher concentrations. MBIC values demonstrated that DHA has a higher efficiency against S. aureus ATCC 43866 with a percentage of BI of 75.13 ± 0.82% at 0.49 µg/mL. Growth curve kinetic profiles of DHA against S. aureus ATCC 25923 were observed to be bacteriostatic. DHA-alginate beads had a average size of 2.37 ± 0.20 and 2.31 ± 0.17 × 10(3) µm(2) with an encapsulation efficiency (EE%) around 99.49 ± 0.05%, a protection percentage (PP%) of 60.00 ± 0.05% in the gastric environment and a protection efficiency (PE%) around 88.12 ± 0.05% against UV light. In toxicological studies DHA has shown IC(50) of 19.59 ± 7.40 µg/mL and a LC(50) of 21.71 ± 2.18%. The obtained results indicate that DHA is a promising antimicrobial candidate against a wide range of bacteria and biofilm formation that must be further explored. MDPI 2021-06-02 /pmc/articles/PMC8229915/ /pubmed/34199531 http://dx.doi.org/10.3390/pharmaceutics13060825 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Neto, Iris
Domínguez-Martín, Eva María
Ntungwe, Epole
Reis, Catarina P.
Pesic, Milica
Faustino, Célia
Rijo, Patrícia
Dehydroabietic Acid Microencapsulation Potential as Biofilm-Mediated Infections Treatment
title Dehydroabietic Acid Microencapsulation Potential as Biofilm-Mediated Infections Treatment
title_full Dehydroabietic Acid Microencapsulation Potential as Biofilm-Mediated Infections Treatment
title_fullStr Dehydroabietic Acid Microencapsulation Potential as Biofilm-Mediated Infections Treatment
title_full_unstemmed Dehydroabietic Acid Microencapsulation Potential as Biofilm-Mediated Infections Treatment
title_short Dehydroabietic Acid Microencapsulation Potential as Biofilm-Mediated Infections Treatment
title_sort dehydroabietic acid microencapsulation potential as biofilm-mediated infections treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229915/
https://www.ncbi.nlm.nih.gov/pubmed/34199531
http://dx.doi.org/10.3390/pharmaceutics13060825
work_keys_str_mv AT netoiris dehydroabieticacidmicroencapsulationpotentialasbiofilmmediatedinfectionstreatment
AT dominguezmartinevamaria dehydroabieticacidmicroencapsulationpotentialasbiofilmmediatedinfectionstreatment
AT ntungweepole dehydroabieticacidmicroencapsulationpotentialasbiofilmmediatedinfectionstreatment
AT reiscatarinap dehydroabieticacidmicroencapsulationpotentialasbiofilmmediatedinfectionstreatment
AT pesicmilica dehydroabieticacidmicroencapsulationpotentialasbiofilmmediatedinfectionstreatment
AT faustinocelia dehydroabieticacidmicroencapsulationpotentialasbiofilmmediatedinfectionstreatment
AT rijopatricia dehydroabieticacidmicroencapsulationpotentialasbiofilmmediatedinfectionstreatment